View Older Stories View More Recent Stories

Jan 20, 2022 04:05PM Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE)
Jan 7, 2022 07:30AM Provention Bio Announces the Grant of Inducement Awards
Jan 6, 2022 07:30AM Provention Bio to Present at the Virtual H.C. Wainwright BioConnect Conference
Dec 20, 2021 07:35AM Provention Bio Inc. (PRVB) Expands Leadership Team
Dec 20, 2021 07:34AM Provention Bio Announces Leadership Team Expansion
Dec 2, 2021 07:30AM Provention Bio Announces the Grant of Inducement Awards
Nov 22, 2021 07:31AM Provention Bio Inc. (PRVB) Issues Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway
Nov 22, 2021 07:30AM Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway
Nov 17, 2021 07:30AM Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development
Nov 9, 2021 08:00AM Provention Bio Puts Type 1 Diabetes to the Test with Pledge Campaign for Diabetes Awareness Month
Nov 5, 2021 04:30PM Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development
Nov 4, 2021 07:07AM Provention Bio Inc. (PRVB) Appoints Thierry Chauche as CFO
Nov 4, 2021 07:05AM Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer
Nov 4, 2021 07:00AM Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
Oct 28, 2021 07:30AM Provention Bio to Report Third Quarter 2021 Financial Results on November 4, 2021
Oct 26, 2021 07:35AM Provention Bio Inc. (PRVB) Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
Oct 26, 2021 07:30AM Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
Sep 23, 2021 07:30AM Provention Bio to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021
Sep 16, 2021 07:30AM Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Sep 13, 2021 07:35AM Provention Bio (PRVB) Provides Update on Potential Timing of Teplizumab At-Risk Type 1 Diabetes Biologics License Application Resubmission
Sep 13, 2021 07:30AM Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission
Aug 5, 2021 07:00AM Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
Jul 29, 2021 07:00AM Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
Jul 12, 2021 07:01AM Provention Bio Inc's. (PRVB) Teplizumab Awarded Innovation Passport in the UK
Jul 12, 2021 07:00AM Teplizumab Awarded Innovation Passport in the United Kingdom (UK) for the Delay of Onset of Clinical Type 1 Diabetes in At-risk Individuals
Jul 6, 2021 07:00AM Provention Bio Inc. (PRVB) Receives CRL to BLA for Teplizumab for Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals
Jul 6, 2021 07:00AM Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals
Jun 2, 2021 07:05AM Provention Bio Announces the Grant of Inducement Awards
Jun 1, 2021 07:05AM Provention Bio to Present at the Jefferies Virtual Healthcare Conference
May 28, 2021 07:07AM Provention Bio (PRVB) Confirms FDA Advisory Committee Votes in Favor of Benefits of Teplizumab Outweighing Risks in Support of Approval to Delay Clinical Type 1 Diabetes
May 27, 2021 09:45PM FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes (T1D)
May 27, 2021 07:06AM Provention Bio (PRVB) Announces Trading Halted Today for FDA Advisory Committee Meeting on Teplizumab
May 27, 2021 07:05AM Provention Bio Stock Trading Halted Today
May 25, 2021 09:31AM Provention Bio Inc. (PRVB) Confirms Posting of Briefing Documents for FDA Advisory Committee Meeting on Teplizumab
May 25, 2021 09:30AM Provention Bio Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Teplizumab
May 6, 2021 07:00AM Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update
May 3, 2021 05:00PM Provention Bio Announces the Grant of Inducement Awards
Apr 29, 2021 04:00PM Provention Bio to Report First Quarter 2021 Financial Results on May 6, 2021
Apr 27, 2021 04:00PM Provention Bio Inc. (PRVB) Provides Additional Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
Apr 27, 2021 04:00PM Provention Bio Provides Additional Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
Apr 8, 2021 04:02PM Provention Bio Inc. (PRVB) says FDA has identified deficiencies for BLA for teplizumab for delay or prevention of clinical type 1 diabetes
Apr 8, 2021 04:01PM Provention Bio Provides Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals
Mar 4, 2021 07:30AM Provention Bio to Present at Two Upcoming Virtual Investor Conferences
Mar 3, 2021 04:01PM Provention Bio Announces Publication of Extended Follow-up Data from the Pivotal "At-Risk" TN-10 Study of Teplizumab in Science Translational Medicine
Feb 25, 2021 07:00AM Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Feb 18, 2021 07:30AM Provention Bio to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Feb 17, 2021 04:01PM Provention Bio Inc. (PRVB) Enters Strategic Collaboration with Huadong in China
Feb 17, 2021 04:00PM Provention Bio and Huadong Announce Strategic Collaboration to Develop and Commercialize PRV-3279 in Greater China
Jan 28, 2021 07:36AM Provention Bio Inc. (PRVB) Announces Key Findings from Pre-clinical Proof-of-concept Study for PRV-3279 for the Prevention of Immunogenicity of Gene Therapy
Jan 28, 2021 07:30AM Provention Bio Announces Key Findings from Pre-clinical Proof-of-concept Study for PRV-3279 for the Prevention of Immunogenicity of Gene Therapy
View More Recent Stories View Older Stories